{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:30:25Z","timestamp":1791174625019,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,4,10]],"date-time":"2008-04-10T00:00:00Z","timestamp":1207785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,4,10]],"date-time":"2008-04-10T00:00:00Z","timestamp":1207785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1038\/leu.2008.80","type":"journal-article","created":{"date-parts":[[2008,4,10]],"date-time":"2008-04-10T10:12:36Z","timestamp":1207822356000},"page":"1117-1124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies"],"prefix":"10.1038","volume":"22","author":[{"given":"A","family":"Quint\u00e1s-Cardama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Manshouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P A","family":"Lennon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Cools","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D G","family":"Gilliland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,4,10]]},"reference":[{"key":"BFleu200880_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/300765a0","volume":"300","author":"A de Klein","year":"1982","unstructured":"de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982; 300: 765\u2013767.","journal-title":"Nature"},{"key":"BFleu200880_CR2","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMra023001","volume":"350","author":"CH Pui","year":"2004","unstructured":"Pui CH, Relling MV, Downing JR . Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535\u20131548.","journal-title":"N Engl J Med"},{"key":"BFleu200880_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/1096-8652(199612)53:4<277::AID-AJH2830530402>3.0.CO;2-Z","volume":"53","author":"GW Colleoni","year":"1996","unstructured":"Colleoni GW, Yamamoto M, Kerbauy J, Serafim RC, Lindsey CJ, Costa FF et al. BCR-ABL rearrangement in adult T-cell acute lymphoblastic leukemia. Am J Hematol 1996; 53: 277\u2013278.","journal-title":"Am J Hematol"},{"key":"BFleu200880_CR4","first-page":"856","volume":"83","author":"F Fabbiano","year":"1998","unstructured":"Fabbiano F, Santoro A, Felice R, Catania P, Cannella S, Majolino I . bcr-abl rearrangement in adult T-lineage acute lymphoblastic leukemia. Haematologica 1998; 83: 856\u2013857.","journal-title":"Haematologica"},{"key":"BFleu200880_CR5","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/sj.leu.2403357","volume":"18","author":"KE Barber","year":"2004","unstructured":"Barber KE, Martineau M, Harewood L, Stewart M, Cameron E, Strefford JC et al. Amplification of the ABL gene in T-cell acute lymphoblastic leukemia. Leukemia 2004; 18: 1153\u20131156.","journal-title":"Leukemia"},{"key":"BFleu200880_CR6","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/ng1425","volume":"36","author":"C Graux","year":"2004","unstructured":"Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004; 36: 1084\u20131089.","journal-title":"Nat Genet"},{"key":"BFleu200880_CR7","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1182\/blood-2006-04-014514","volume":"108","author":"T Burmeister","year":"2006","unstructured":"Burmeister T, Gokbuget N, Reinhardt R, Rieder H, Hoelzer D, Schwartz S . NUP214-ABL1 in adult T-ALL: the GMALL study group experience. Blood 2006; 108: 3556\u20133557.","journal-title":"Blood"},{"key":"BFleu200880_CR8","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2032Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408\u20132417.","journal-title":"N Engl J Med"},{"key":"BFleu200880_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129\u2013141.","journal-title":"Cancer Cell"},{"key":"BFleu200880_CR10","first-page":"159","volume":"46","author":"F Lee","year":"2005","unstructured":"Lee F, Lombardo L, Camuso A, Castaneda S, Fager K, Flefleh C et al. BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad spectrum anti-tumor activities in vitro and in vivo. Proc Am Assoc Cancer Res 2005; 46: 159 (abstr 675).","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BFleu200880_CR11","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658\u20136661.","journal-title":"J Med Chem"},{"key":"BFleu200880_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL . Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399\u2013401.","journal-title":"Science"},{"key":"BFleu200880_CR13","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","volume":"109","author":"J Cortes","year":"2007","unstructured":"Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109: 3207\u20133213.","journal-title":"Blood"},{"key":"BFleu200880_CR14","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/ijc.2910250604","volume":"25","author":"Z Ravid","year":"1980","unstructured":"Ravid Z, Goldblum N, Zaizov R, Schlesinger M, Kertes T, Minowada J et al. Establishment and characterization of a new leukaemic T-cell line (Peer) with an unusual phenotype. Int J Cancer 1980; 25: 705\u2013710.","journal-title":"Int J Cancer"},{"key":"BFleu200880_CR15","first-page":"425","volume":"8","author":"M Heyman","year":"1994","unstructured":"Heyman M, Grander D, Brondum-Nielsen K, Cederblad B, Liu Y, Xu B et al. Interferon system defects in malignant T-cells. Leukemia 1994; 8: 425\u2013434.","journal-title":"Leukemia"},{"key":"BFleu200880_CR16","unstructured":"http:\/\/www.ncbi.nlm.nih.gov\/. Accessed April 24, 2007."},{"key":"BFleu200880_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55\u201363.","journal-title":"J Immunol Methods"},{"key":"BFleu200880_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1182\/blood-2006-04-013805","volume":"109","author":"J Pan","year":"2007","unstructured":"Pan J, Quintas-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P et al. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 2007; 109: 315\u2013322.","journal-title":"Blood"},{"key":"BFleu200880_CR19","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1158\/0008-5472.CAN-04-2744","volume":"65","author":"J Pan","year":"2005","unstructured":"Pan J, She M, Xu ZX, Sun L, Yeung SC . Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells. Cancer Res 2005; 65: 3671\u20133681.","journal-title":"Cancer Res"},{"key":"BFleu200880_CR20","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1002\/cncr.20668","volume":"101","author":"H Kantarjian","year":"2004","unstructured":"Kantarjian H, Thomas D, O\u2032Brien S, Cortes J, Giles F, Jeha S et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004; 101: 2788\u20132801.","journal-title":"Cancer"},{"key":"BFleu200880_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fannning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561\u2013566.","journal-title":"Nat Med"},{"key":"BFleu200880_CR22","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood.V84.9.2912.2912","volume":"84","author":"GL Nichols","year":"1994","unstructured":"Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW . Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 1994; 84: 2912\u20132918.","journal-title":"Blood"},{"key":"BFleu200880_CR23","doi-asserted-by":"crossref","first-page":"22925","DOI":"10.1016\/S0021-9258(17)31596-X","volume":"269","author":"T Oda","year":"1994","unstructured":"Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ . Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 1994; 269: 22925\u201322928.","journal-title":"J Biol Chem"},{"key":"BFleu200880_CR24","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.V84.6.1731.1731","volume":"84","author":"J ten Hoeve","year":"1994","unstructured":"ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J . Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. Blood 1994; 84: 1731\u20131736.","journal-title":"Blood"},{"key":"BFleu200880_CR25","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1126\/science.1708916","volume":"252","author":"CA Koch","year":"1991","unstructured":"Koch CA, Anderson D, Moran MF, Ellis C, Pawson T . SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science 1991; 252: 668\u2013674.","journal-title":"Science"},{"key":"BFleu200880_CR26","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1182\/blood-2005-03-1103","volume":"106","author":"D White","year":"2005","unstructured":"White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005; 106: 2520\u20132526.","journal-title":"Blood"},{"key":"BFleu200880_CR27","doi-asserted-by":"publisher","first-page":"35631","DOI":"10.1074\/jbc.M005401200","volume":"275","author":"BB Brasher","year":"2000","unstructured":"Brasher BB, Van Etten RA . c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J Biol Chem 2000; 275: 35631\u201335637.","journal-title":"J Biol Chem"},{"key":"BFleu200880_CR28","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/sj.leu.2403654","volume":"19","author":"P Ballerini","year":"2005","unstructured":"Ballerini P, Busson M, Fasola S, van den Akker J, Lapillonne H, Romana SP et al. NUP214-ABL1 amplification in t(5;14)\/HOX11L2-positive ALL present with several forms and may have a prognostic significance. Leukemia 2005; 19: 468\u2013470.","journal-title":"Leukemia"},{"key":"BFleu200880_CR29","doi-asserted-by":"publisher","first-page":"518a","DOI":"10.1182\/blood-2005-09-3691","volume":"108","author":"K De Keersmaecker","year":"2006","unstructured":"De Keersmaecker K, Bernard R, Folens C, Mentens N, Marynen P, Fornerodet M et al. Oncogenic properties of the T-ALL-associated EML1-ABL1 and NUP214-ABL1 fusion proteins. Blood 2006; 108: 518a (abstr 1830).","journal-title":"Blood"},{"key":"BFleu200880_CR30","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1073\/pnas.91.4.1519","volume":"91","author":"D Kraemer","year":"1994","unstructured":"Kraemer D, Wozniak RW, Blobel G, Radu A . The human CAN protein, a putative oncogene product associated with myeloid leukemogenesis, is a nuclear pore complex protein that faces the cytoplasm. Proc Natl Acad Sci USA 1994; 91: 1519\u20131523.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu200880.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu200880","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu200880.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T12:23:32Z","timestamp":1648729412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu200880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,10]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["BFleu200880"],"URL":"https:\/\/doi.org\/10.1038\/leu.2008.80","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,10]]},"assertion":[{"value":"17 September 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2008","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2008","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2008","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}